VivaCell Biotechnology España Announces the Award of a Significant €1.9 Million Project Grant for a Phase II Clinical Trial on Etrinabdione, a “first-in-class” Cannabinoid Derivative with Vasculogenic Properties.
Córdoba, 11 December 2024 – VivaCell, a leading company in the development of synthetic and semisynthetic drug candidates, proudly announces the award of a €1.9 million project to conduct a Phase IIa clinical trial of its experimental drug Etrinabdione, a first-in-class PP2A/B55a activator with vasculogenic properties aimed at treating peripheral arterial disease (PAD). This project grant has been published by the Agencia Estatal de Investigación (AEI) in the call for Public-Private Collaboration Projects 2023 with the title “Phase IIa clinical trial with Etrinabdione in patients with peripheral arterial disease (CPP2023-010650)”.
The clinical trial will be carried out in collaboration with the Maimonides Biomedical Research Institute of Córdoba (IMIBIC) and the Reina Sofía University Hospital, two esteemed institutions recognized for their excellence in cardiovascular research and treatment. The trial will be led by Dr. Ignacio Muñoz, Head of the Cardiovascular Department at Reina Sofía Hospital, whose expertise will be pivotal to the project’s success.
Etrinabdione will be evaluated in 30 patients suffering from PAD, a condition characterized by restricted blood flow to the extremities with limited treatment options currently available. This Phase IIa trial will assess the drug’s efficacy and safety, aiming to provide a novel therapeutic option leveraging its vasculogenic properties. The first patient is expected to be dosed in April 2025.
Prof. Eduardo Muñoz, Scientific Advisor and co-founder of VivaCell, commented: “Securing this €1.9 million grant for the Phase IIa trial of Etrinabdione is a pivotal achievement for VivaCell. Collaborating with IMIBIC and Reina Sofía Hospital, under the leadership of Dr. Ignacio Muñoz, positions us to advance the development of a groundbreaking treatment for peripheral arterial disease.”
About VivaCell
VivaCell is a pioneering pharmaceutical company specializing in the research and development of innovative therapies for challenging conditions such as peripheral arterial disease. With a strong track record in developing cannabinoid-based solutions, VivaCell remains committed to enhancing patients’ quality of life through innovation and strategic partnerships in the healthcare sector.
For more information, please contact: info@vivacellspain.com
Project CPP2023-010650 funded by:
INDEGESICA
Córdoba, March 31th 2022. The Spanish Ministry of Science and Innovation has granted to Vivacell with the financial support to continue the Preclinical research and further development of new allosteric modulators of the CB1R receptor with analgesic activity. The Project INDEGESICA has a CDTI contribution of 382.874,02€ for two years. It is coordinated and performed by Vivacell. The project has received CDTI funding coming from the Ministry of Science and Innovation
